Citigroup Maintains Buy on IDEAYA Biosciences, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on IDEAYA Biosciences (IDYA) and raises the price target from $40 to $60.
March 21, 2024 | 4:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on IDEAYA Biosciences and raises the price target from $40 to $60.
The upgrade in price target by a reputable analyst from Citigroup is a strong positive signal for IDEAYA Biosciences. It suggests a bullish outlook on the company's future performance, potentially leading to increased investor confidence and a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100